Rifaximin plus N-acetylcysteine for irritable bowel syndrome with diarrhea
Tests rifaximin combined with N-acetylcysteine in adults with diarrhea-predominant irritable bowel syndrome.
Key facts
- Who runs it
- Mark Pimentel, MD
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Efficacy of Rifaximin With NAC in IBS-D
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 225 people, planned
- Started
- 4 Feb 2026
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- rifaximin 66mg + N-acetylcysteine 560mg three times daily
- RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
- Placebo
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome with diarrhea (IBS-D) whose symptoms are not well relieved. It tests rifaximin combined with NAC against placebo.
- Age
- 18 years or older
- Sex
- Men and women. Women cannot be pregnant or breastfeeding.
- Disease stage
- IBS confirmed by the Rome IV criteria, with diarrhea. During screening, the weekly average of worst daily belly pain must be above 3.0 on a 0-10 scale. At least one stool must be Type 6 or 7 on the Bristol scale (loose or watery).
- Earlier treatment
- People cannot currently use NAC or rifaximin. No antibiotics taken by mouth or injection in the last month.
Main reasons for not taking part
- Signs of IBS with constipation (fewer than 3 bowel movements a week, hard stools, heavy straining)
- History of inflammatory bowel disease, celiac disease or gut surgery (except gallbladder or appendix removal)
- Active stomach or duodenal ulcer, diverticulitis or gut infection
- Current asthma
- Serious liver, kidney, heart, lung, thyroid, diabetes or mental health condition that the doctor thinks rules out joining
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or non-pregnant, non-lactating female patients ≥ 18 years of age
- Diagnosed with IBS confirmed by the Rome IV criteria, with associated symptoms of diarrhea as noted below in 4(b)
- Do not have adequate relief of IBS symptoms of abdominal pain, stool consistency or stool frequency
- Have daily IBS symptom scores during screening as below:; Weekly average score of worst daily abdominal pain >3.0 on a 0-10 point scale; At least one stool with a consistency of Type 6 or 7 on the Bristol
Who cannot take part
- Not currently on a prokinetic drug
- History of inflammatory bowel disease, celiac disease, GI surgery (except cholecystectomy and/or appendectomy)
- Evidence of active duodenal ulcer, gastric ulcer, diverticulitis, or active infectious gastroenteritis
- A significant medical condition including but not limited to hepatic, uncontrolled diabetes, renal, cardiovascular, pulmonary, uncontrolled thyroid disease. or psychiatric disease, which in the opinion of investigator precludes study participation
- Present with the following symptoms of IBS with constipation:; Less than 3 bowel movements a week,; Hard or lumpy stools, and; Excessive straining during a bowel movement
- Current diagnosis of asthma
- Current user of NAC and/or rifaximin
- Systemic antibiotic use in the last month
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Ava HosseiniTaking people
About the trial
What the trial wants to find out
The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is one of the standard treatments for IBS-D and is FDA approved. While rifaximin is safe and effective for treating symptoms in patients with IBS-D, many patients find that their symptoms may not completely resolve, or may come back after a period of time.
Read full original descriptionShow less
This research study is designed to test the investigational use of a combination of rifaximin and NAC. The combination of rifaximin and NAC is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of IBS-D, and the effects of taking both medications together are unknown. However, the two medications are approved for use separately, as detailed below.
Rifaximin is the only antibiotic approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 550 mg by mouth three times daily for 14 days) is approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 200 mg per mouth three times daily for 3 days) is FDA approved for the treatment of traveler's diarrhea. Rifaximin at a dose of 200 mg per mouth three times daily is not approved by the FDA for the treatment of IBS-D.
NAC is approved by the FDA to treat acetaminophen overdose (72-hour oral and 21-hour intravenous (IV) regimens), and for use in breaking up mucus in the lungs in patients with chronic obstructive pulmonary disease (COPD) and other lung conditions such as bronchitis. NAC is also available over-the-counter in 600 mg and 900 mg capsules as a dietary supplement, although over-the-counter use is not regulated by the FDA. This study will utilize the 600 mg dietary supplement capsules.
The Investigators want to know if using a combination of rifaximin and NAC will give better results in decreasing IBS-D symptoms than using rifaximin alone. As NAC is used to break up mucus in the lungs, and the Investigators want to see if this can also break up the mucus layer in the small intestine, and therefore potentially increase the effectiveness of rifaximin. The Investigators will be testing 2 doses to determine which dose is most effective.
participants are being asked to take part in this research study because participants were diagnosed with IBS-D.
The 3 groups in the trial
- low dose for IBS-DTreatment being tested
RNIB21 containing rifaximin 66mg + NAC 560mg three times a day
Treatment: rifaximin 66mg + N-acetylcysteine 560mg three times daily
- high dose for IBS-DTreatment being tested
RNIB21 containing rifaximin 132mg + NAC 560mg three times a day
Treatment: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
- placeboPlacebo, for comparison
placebo three times a day
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Plain-language title
- Rifaximin plus N-acetylcysteine for irritable bowel syndrome with diarrheaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 April 2026